ArticleFrontiers in oncology2025
Inflammation as a key mediator: linking triglyceride-glucose index to prognosis in non-muscle-invasive bladder cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of TyG-BMI and malnutrition with reduced survival outcomes in patients with cancer: a prospective study.Frontiers in nutrition · 2026Article
- Emotional stress: a prominent factor positively related to the onset and recurrence of bladder cancer as revealed by NHANES and a Chinese database.Annals of medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder carcinoma (BCa) is a prevalent urological malignancy characterised by high recurrence and progression rates, posing significant challenges in clinical management. The triglyceride-glucose (TyG) index has emerged as a promising prognostic marker for metabolic health in various cancers. This study explores the prognostic value of the TyG index in non-muscle-invasive bladder cancer (NMIBC), with a focus on its association with high-grade recurrence-free survival (RFS) and progression-free survival (PFS) and the mediating role of systemic inflammation. Methods: A total of 230 patients diagnosed with NMIBC between October 2017 and October 2022 were included in this retrospective study. Clinical and pathological data were collected alongside follow-up treatment outcomes. Mediation analysis was conducted to quantify the role of systemic inflammation, using markers such as C-reactive protein (CRP), interleukin-6 (IL-6), and interleukin-8 (IL-8), in the relationship between the TyG index and patient prognosis. Results: The TyG index was identified as a significant, non-linear prognostic factor for both RFS and PFS. An inverted U-shaped relationship was observed, with inflexion points at 9.186 and 9.168 for RFS and PFS, respectively. Below these thresholds, the TyG index was positively associated with worse outcomes (RFS: HR = 3.37, 95% CI = 1.77-6.41, Conclusion: These findings suggest that the TyG index could serve as a valuable tool for risk stratification and prognostic assessment in NMIBC. Its integration into clinical decision-making frameworks may improve personalised management strategies, particularly by targeting systemic inflammation as a modifiable factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.